CN111888474A - 治疗髓性白血病的表观遗传因子和靶向cd33与cd3的双特异性化合物的组合 - Google Patents

治疗髓性白血病的表观遗传因子和靶向cd33与cd3的双特异性化合物的组合 Download PDF

Info

Publication number
CN111888474A
CN111888474A CN202010532460.4A CN202010532460A CN111888474A CN 111888474 A CN111888474 A CN 111888474A CN 202010532460 A CN202010532460 A CN 202010532460A CN 111888474 A CN111888474 A CN 111888474A
Authority
CN
China
Prior art keywords
ser
gly
thr
leukemia
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010532460.4A
Other languages
English (en)
Chinese (zh)
Inventor
R·B·沃尔特
M·萨布克利韦
C·克鲁普卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Amgen Inc
Original Assignee
Amgen Research Munich GmbH
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH, Amgen Inc filed Critical Amgen Research Munich GmbH
Publication of CN111888474A publication Critical patent/CN111888474A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202010532460.4A 2013-09-13 2014-09-15 治疗髓性白血病的表观遗传因子和靶向cd33与cd3的双特异性化合物的组合 Pending CN111888474A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361877714P 2013-09-13 2013-09-13
US61/877,714 2013-09-13
CN201480061643.5A CN105764505A (zh) 2013-09-13 2014-09-15 治疗髓性白血病的表观遗传因子和靶向cd33与cd3的双特异性化合物的组合

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480061643.5A Division CN105764505A (zh) 2013-09-13 2014-09-15 治疗髓性白血病的表观遗传因子和靶向cd33与cd3的双特异性化合物的组合

Publications (1)

Publication Number Publication Date
CN111888474A true CN111888474A (zh) 2020-11-06

Family

ID=51690351

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480061643.5A Pending CN105764505A (zh) 2013-09-13 2014-09-15 治疗髓性白血病的表观遗传因子和靶向cd33与cd3的双特异性化合物的组合
CN202010532460.4A Pending CN111888474A (zh) 2013-09-13 2014-09-15 治疗髓性白血病的表观遗传因子和靶向cd33与cd3的双特异性化合物的组合

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201480061643.5A Pending CN105764505A (zh) 2013-09-13 2014-09-15 治疗髓性白血病的表观遗传因子和靶向cd33与cd3的双特异性化合物的组合

Country Status (27)

Country Link
US (1) US10933132B2 (enExample)
EP (1) EP3043794B1 (enExample)
JP (1) JP6530409B2 (enExample)
KR (1) KR102366470B1 (enExample)
CN (2) CN105764505A (enExample)
AP (1) AP2016009132A0 (enExample)
AR (1) AR097648A1 (enExample)
AU (2) AU2014320246B2 (enExample)
CA (1) CA2923354C (enExample)
CL (1) CL2016000564A1 (enExample)
DK (1) DK3043794T3 (enExample)
EA (1) EA036476B1 (enExample)
HU (1) HUE056867T2 (enExample)
IL (1) IL278527B (enExample)
JO (1) JO3597B1 (enExample)
LT (1) LT3043794T (enExample)
MA (2) MA46164B1 (enExample)
MX (1) MX381852B (enExample)
MY (1) MY185611A (enExample)
NZ (1) NZ716448A (enExample)
PH (1) PH12016500434B1 (enExample)
SG (2) SG10201801777YA (enExample)
SI (1) SI3043794T1 (enExample)
TW (1) TWI688401B (enExample)
UA (1) UA123199C2 (enExample)
WO (1) WO2015036583A2 (enExample)
ZA (1) ZA201600528B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112630438A (zh) * 2021-03-08 2021-04-09 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查髓系疾病及检测免疫检查点的应用
CN113461821A (zh) * 2021-09-03 2021-10-01 苏州近岸蛋白质科技股份有限公司 抗cd3人源化抗体
CN113533729A (zh) * 2021-06-15 2021-10-22 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
CN114908087A (zh) * 2022-05-07 2022-08-16 四川大学华西医院 一种长循环肾靶向细胞外囊泡的构建及其应用

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
JP2018516248A (ja) 2015-05-29 2018-06-21 アンフィヴェナ セラピューティクス，インク． 二重特異性のｃｄ３３およびｃｄ３結合タンパク質を使用する方法
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EP3390653B1 (en) 2015-12-16 2022-08-10 F. Hoffmann-La Roche AG Improved recombinant production method
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
IL260920B (en) 2016-02-03 2022-09-01 Amgen Res Munich Gmbh Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
EP3600419B1 (en) * 2017-03-20 2023-08-09 Vaccinex, Inc. Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
KR102090407B1 (ko) * 2017-11-24 2020-03-17 충북대학교 산학협력단 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물
WO2019103531A1 (ko) * 2017-11-24 2019-05-31 충북대학교 산학협력단 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물
US11597933B2 (en) 2017-11-29 2023-03-07 The Trustees Of Columbia University In The City Of New York Combination therapy of lymphoma
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
EP3830121A1 (en) * 2018-07-30 2021-06-09 Amgen Research (Munich) GmbH Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
EP3849565A4 (en) 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
CN113045664B (zh) 2019-11-28 2023-05-12 尚健单抗（北京）生物技术有限公司 一种分离的结合抗原axl的蛋白及其用途
US20230146121A1 (en) 2019-12-09 2023-05-11 Chigenovo Co., Ltd. Use of cyp4v2 and rdcvf in the manufacture of medicament
CN112079934B (zh) 2019-12-17 2021-01-29 合源生物科技(天津)有限公司 一种靶向cd19的嵌合抗原受体及其用途
US20230117361A1 (en) * 2019-12-26 2023-04-20 Agency For Science, Technology And Research Composition comprising mir-335
CN115003802B (zh) 2020-01-02 2024-09-03 宁波茂行生物医药科技有限公司 一种经修饰的免疫效应细胞及其制备方法
CN113481165B (zh) * 2020-07-16 2022-06-03 山东博安生物技术股份有限公司 分泌双特异性t细胞衔接子的car-t及治疗实体肿瘤的应用
CN111733174B (zh) 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
US20240026024A1 (en) 2020-12-11 2024-01-25 Shanghai Huaota Biopharmaceutical Co., Ltd. Cd73 antigen-binding protein and application thereof
CN117062908A (zh) 2021-01-11 2023-11-14 星济生物(苏州)有限公司 靶向金黄色葡萄球菌α-毒素的抗原结合蛋白及其应用
US20240067747A1 (en) 2021-01-13 2024-02-29 Shanghai Huaota Biopharmaceutical Co., Ltd. Cd73-binding protein and use thereof
BR112023019358A2 (pt) 2021-03-22 2023-12-26 Starmab Biologics Shanghai Co Ltd Proteína de ligação a antígeno direcionada à hemolisina de streptococcus pneumoniae e uso do mesmo
EP4299593A4 (en) 2021-04-02 2025-12-10 Oricell Therapeutics Co Ltd CLDN18.2 ANTIGEN-BINDING PROTEIN AND ITS USE
CN115612674A (zh) 2021-07-14 2023-01-17 上海荣瑞医药科技有限公司 一种溶瘤病毒及其用途
CN119709650A (zh) 2022-01-26 2025-03-28 上海荣瑞医药科技有限公司 溶瘤病毒及其应用
US20250361314A1 (en) 2022-06-08 2025-11-27 Shanghai Huaota Biopharmaceutical Co., Ltd. Cd39/cd73 bispecific antigen binding protein and use thereof
CN117362433A (zh) 2022-06-30 2024-01-09 杭州尚健生物技术有限公司 分离的抗原结合蛋白及其用途
CN117402836A (zh) 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 重组溶瘤病毒及其应用
CN117402837A (zh) 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 一种重组溶瘤病毒及其应用
JP2025532675A (ja) 2022-09-23 2025-10-01 ロングバイオ ファーマ （スーチョウ） カンパニー、リミテッド ＦｃεＲＩ結合タンパク質
WO2024153050A1 (zh) 2023-01-17 2024-07-25 苏州永心生物科技有限公司 Dr5结构域变体及其应用
CN116350759A (zh) 2023-03-30 2023-06-30 上海荣瑞医药科技有限公司 溶瘤病毒疫苗和免疫细胞联合治疗肿瘤的方法
CN117085048A (zh) 2023-07-26 2023-11-21 上海荣瑞医药科技有限公司 重组溶瘤病毒和小分子抗癌药联合治疗肿瘤的方法
CN118221826B (zh) * 2024-04-25 2024-11-15 北京绿竹生物技术股份有限公司 一种结合人cd33和cd3的双特异性抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110038856A1 (en) * 2006-11-02 2011-02-17 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
ES2142801T3 (es) 1991-03-11 2000-05-01 Univ Georgia Res Found Clonacion y expresion de luciferasa de renilla.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
DE69435112D1 (de) 1993-09-10 2008-08-21 Univ Columbia Verwendung von grünem fluoreszenzprotein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
JP3795533B2 (ja) 1996-12-12 2006-07-12 プロルーム・リミテツド 感染性物質を検出及び同定するための方法及び装置
WO1999049019A2 (en) 1998-03-27 1999-09-30 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
JP4169478B2 (ja) 1998-04-21 2008-10-22 マイクロメット アーゲー Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
US20050025823A1 (en) * 2003-07-29 2005-02-03 Fong Andy A.T. Methods of use of herbal compositions
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
DK1940881T3 (en) 2005-10-11 2017-02-20 Amgen Res Munich Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
FI2155783T4 (fi) 2007-04-03 2022-12-15 Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110038856A1 (en) * 2006-11-02 2011-02-17 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AIGNER等: "T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct", 《LEUKEMIA》 *
ERIC SANCHEZ等: "The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo", 《LEUKEMIA RESEARCH》 *
P MAISO等: "The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair", 《LEUKEMIA》 *
PATRICIA MAISO等: "The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance", 《CANCER RES》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112630438A (zh) * 2021-03-08 2021-04-09 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查髓系疾病及检测免疫检查点的应用
CN112630438B (zh) * 2021-03-08 2021-06-22 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查髓系疾病及检测免疫检查点的应用
CN113533729A (zh) * 2021-06-15 2021-10-22 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
CN113461821A (zh) * 2021-09-03 2021-10-01 苏州近岸蛋白质科技股份有限公司 抗cd3人源化抗体
CN114908087A (zh) * 2022-05-07 2022-08-16 四川大学华西医院 一种长循环肾靶向细胞外囊泡的构建及其应用
CN114908087B (zh) * 2022-05-07 2024-01-23 四川大学华西医院 一种长循环肾靶向细胞外囊泡的构建及其应用

Also Published As

Publication number Publication date
IL278527A (enExample) 2020-12-31
DK3043794T3 (da) 2021-11-15
NZ716448A (en) 2022-02-25
UA123199C2 (uk) 2021-03-03
CL2016000564A1 (es) 2017-03-24
MX381852B (es) 2025-03-13
EP3043794B1 (en) 2021-09-01
EA201690485A1 (ru) 2016-08-31
JO3597B1 (ar) 2020-07-05
MA38898A1 (fr) 2018-01-31
KR20160058120A (ko) 2016-05-24
SI3043794T1 (sl) 2021-11-30
US10933132B2 (en) 2021-03-02
WO2015036583A3 (en) 2015-07-02
MY185611A (en) 2021-05-25
TW201605473A (zh) 2016-02-16
LT3043794T (lt) 2021-10-25
EP3043794A2 (en) 2016-07-20
AU2014320246A1 (en) 2016-02-18
CN105764505A (zh) 2016-07-13
US20160317657A1 (en) 2016-11-03
CA2923354C (en) 2022-11-29
PH12016500434A1 (en) 2016-05-16
JP6530409B2 (ja) 2019-06-12
KR102366470B1 (ko) 2022-02-24
MA46164A1 (fr) 2020-12-31
SG10201801777YA (en) 2018-04-27
HUE056867T2 (hu) 2022-03-28
MA46164B1 (fr) 2021-04-30
AU2014320246B2 (en) 2020-01-23
WO2015036583A2 (en) 2015-03-19
HK1225975A1 (zh) 2017-09-22
IL278527B (en) 2022-07-01
PH12016500434B1 (en) 2016-05-16
TWI688401B (zh) 2020-03-21
CA2923354A1 (en) 2015-03-19
ZA201600528B (en) 2021-06-30
MX2016003197A (es) 2016-06-02
AR097648A1 (es) 2016-04-06
AP2016009132A0 (en) 2016-04-30
SG11201600671QA (en) 2016-02-26
EA036476B1 (ru) 2020-11-13
JP2016536341A (ja) 2016-11-24
AU2020202641A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
KR102366470B1 (ko) 골수성 백혈병의 치료에서 후성적 인자와 cd33 및 cd3을 표적화하는 이중특이적 화합물의 배합물
JP6880100B2 (ja) Ｃｄｈ１９およびｃｄ３に対する抗体構築物
US20240166761A1 (en) Single chain binding molecules comprising N-terminal ABP
JP6879998B2 (ja) Ｃｄ７０及びｃｄ３に対する抗体構築物
JP7189141B2 (ja) Ｔ細胞エンゲージ抗体コンストラクトを含む低ｐＨ医薬組成物
JP7605913B2 (ja) Ｍｕｃ１７及びｃｄ３に向けられる二重特異性抗体コンストラクト
KR20180030852A (ko) Flt3 및 cd3을 위한 항체 작제물
JP2018530996A6 (ja) Ｃｄ７０及びｃｄ３に対する抗体構築物
CN116063541A (zh) 用于cdh3和cd3的双特异性抗体构建体
TW202136300A (zh) 用於在增殖性疾病中使用的多靶向抗原結合分子
CN117279947A (zh) 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
TW202346368A (zh) 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
HK1225975B (en) Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201106

WD01 Invention patent application deemed withdrawn after publication